S&P 500   3,069.07 (-1.52%)
DOW   26,539.84 (-1.55%)
QQQ   211.99 (-2.07%)
AAPL   281.75 (-3.72%)
FB   194.27 (-1.49%)
MSFT   165.43 (-2.79%)
GOOGL   1,354.64 (-2.58%)
CGC   19.32 (-2.52%)
NVDA   260.35 (-2.73%)
BABA   207.63 (-0.53%)
MU   51.72 (-1.24%)
GE   10.84 (-1.01%)
TSLA   713.30 (-8.41%)
AMD   44.92 (-5.41%)
T   36.59 (-1.37%)
F   7.21 (+0.00%)
NFLX   386.52 (+1.92%)
BAC   30.04 (-1.93%)
DIS   121.78 (-1.28%)
GILD   74.51 (-0.25%)
S&P 500   3,069.07 (-1.52%)
DOW   26,539.84 (-1.55%)
QQQ   211.99 (-2.07%)
AAPL   281.75 (-3.72%)
FB   194.27 (-1.49%)
MSFT   165.43 (-2.79%)
GOOGL   1,354.64 (-2.58%)
CGC   19.32 (-2.52%)
NVDA   260.35 (-2.73%)
BABA   207.63 (-0.53%)
MU   51.72 (-1.24%)
GE   10.84 (-1.01%)
TSLA   713.30 (-8.41%)
AMD   44.92 (-5.41%)
T   36.59 (-1.37%)
F   7.21 (+0.00%)
NFLX   386.52 (+1.92%)
BAC   30.04 (-1.93%)
DIS   121.78 (-1.28%)
GILD   74.51 (-0.25%)
S&P 500   3,069.07 (-1.52%)
DOW   26,539.84 (-1.55%)
QQQ   211.99 (-2.07%)
AAPL   281.75 (-3.72%)
FB   194.27 (-1.49%)
MSFT   165.43 (-2.79%)
GOOGL   1,354.64 (-2.58%)
CGC   19.32 (-2.52%)
NVDA   260.35 (-2.73%)
BABA   207.63 (-0.53%)
MU   51.72 (-1.24%)
GE   10.84 (-1.01%)
TSLA   713.30 (-8.41%)
AMD   44.92 (-5.41%)
T   36.59 (-1.37%)
F   7.21 (+0.00%)
NFLX   386.52 (+1.92%)
BAC   30.04 (-1.93%)
DIS   121.78 (-1.28%)
GILD   74.51 (-0.25%)
S&P 500   3,069.07 (-1.52%)
DOW   26,539.84 (-1.55%)
QQQ   211.99 (-2.07%)
AAPL   281.75 (-3.72%)
FB   194.27 (-1.49%)
MSFT   165.43 (-2.79%)
GOOGL   1,354.64 (-2.58%)
CGC   19.32 (-2.52%)
NVDA   260.35 (-2.73%)
BABA   207.63 (-0.53%)
MU   51.72 (-1.24%)
GE   10.84 (-1.01%)
TSLA   713.30 (-8.41%)
AMD   44.92 (-5.41%)
T   36.59 (-1.37%)
F   7.21 (+0.00%)
NFLX   386.52 (+1.92%)
BAC   30.04 (-1.93%)
DIS   121.78 (-1.28%)
GILD   74.51 (-0.25%)
Log in

NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News

$218.88
-2.70 (-1.22 %)
(As of 02/27/2020 12:26 PM ET)
Today's Range
$214.57
Now: $218.88
$220.42
50-Day Range
$219.86
MA: $231.63
$242.99
52-Week Range
$165.69
Now: $218.88
$247.64
Volume884,698 shs
Average Volume1.40 million shs
Market Capitalization$45.77 billion
P/E Ratio44.31
Dividend YieldN/A
Beta0.78
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP28176E10
Phone949-250-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.35 billion
Cash Flow$5.96 per share
Book Value$19.84 per share

Profitability

Net Income$1.05 billion

Miscellaneous

Employees13,900
Market Cap$45.77 billion
Next Earnings Date4/28/2020 (Estimated)
OptionableOptionable

Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.


Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Shares of Edwards Lifesciences split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were distributed to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corp (NYSE:EW) released its earnings results on Thursday, January, 30th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.49 by $0.03. The medical research company had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.15 billion. Edwards Lifesciences had a net margin of 24.08% and a return on equity of 31.73%. The firm's quarterly revenue was up 20.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.17 EPS. View Edwards Lifesciences' Earnings History.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Edwards Lifesciences.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of $6.15-6.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.98. The company issued revenue guidance of $4.6-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

What price target have analysts set for EW?

22 Wall Street analysts have issued twelve-month price objectives for Edwards Lifesciences' stock. Their forecasts range from $159.00 to $300.00. On average, they anticipate Edwards Lifesciences' share price to reach $250.38 in the next year. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.

What is the consensus analysts' recommendation for Edwards Lifesciences?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 sell ratings, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

What are Wall Street analysts saying about Edwards Lifesciences stock?

Here are some recent quotes from research analysts about Edwards Lifesciences stock:
  • 1. According to Zacks Investment Research, "Edwards Lifesciences exited the fourth quarter of 2019 on a mixed note with lower-than-expected earnings and a revenue beat. Globally, TAVR procedures increased on strong therapy adoption across all geographies. We are also upbeat about strong sales growth within the Critical Care segment, driven by robust demand for the HemoSphere advance monitoring platform and continued adoption of Smart Recovery. The company continued benefiting from its CASMED acquisition. Moreover, a lifted 2020 EPS guidance raises investors’ optimism on the stock. In the past year, shares of Edwards Lifesciences have outperformed the industry. Meanwhile, dismal performances within Surgical Structural Heart and TMTT segments raise concern. Also, escalating costs put pressure on the margins in the fourth quarter." (2/3/2020)
  • 2. BTIG Research analysts commented, "As we cautioned in our Q1 preview, TAVR results missed Street estimates. While we have no doubt that the underlying market remains strong, results have been light for 4+ quarters now, making us question if the market growth is a tad less than expected or if share is slightly shifting. Even so, management maintained an upbeat tone and there was no change to TAVR guidance but with Boston Scientific’s (BSX, Lotus approved in the U.S. tonight, we have to think that combined with weak Q1 results, shares may see pressure. On longer-term drivers, mitral sales were $4M in Q1 and although early feedback on PASCAL has fostered management’s own confidence in its outlook, we feel hitting $40M in revenue this year is a lofty goal. On the positive side, we would point to management’s bullishness on the revenue ramp in 2H and the solid expense control driving the EPS beat." (4/24/2019)

Has Edwards Lifesciences been receiving favorable news coverage?

Media coverage about EW stock has trended negative on Thursday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Edwards Lifesciences earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Edwards Lifesciences.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 2,040,000 shares, a drop of 14.3% from the January 30th total of 2,380,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.0% of the company's stock are short sold. View Edwards Lifesciences' Current Options Chain.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Mastercard (MA), Broadcom (AVGO), Gilead Sciences (GILD) and QUALCOMM (QCOM).

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the folowing people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 66)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)
  • Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. Controller
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.28%), FMR LLC (3.88%), Bank of New York Mellon Corp (2.97%), Sands Capital Management LLC (2.91%), Jennison Associates LLC (2.35%) and Capital Research Global Investors (2.24%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

Which major investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Jennison Associates LLC, Alliancebernstein L.P., Thrivent Financial for Lutherans, Marshall Wace North America L.P., Bank of New York Mellon Corp, Bessemer Group Inc. and Partner Fund Management L.P.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

Which major investors are buying Edwards Lifesciences stock?

EW stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, FMR LLC, UBS Asset Management Americas Inc., Amundi Pioneer Asset Management Inc., Prudential Financial Inc., William Blair Investment Management LLC, Captrust Financial Advisors and Skandinaviska Enskilda Banken AB publ . View Insider Buying and Selling for Edwards Lifesciences.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $220.22.

How big of a company is Edwards Lifesciences?

Edwards Lifesciences has a market capitalization of $46.05 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $5.57 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.View Additional Information About Edwards Lifesciences.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is http://www.edwards.com/.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]


MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  1,155 (Vote Outperform)
Underperform Votes:  813 (Vote Underperform)
Total Votes:  1,968
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel